홈IMMP • NASDAQ
add
Immutep Ltd - ADR
뉴스
재무
손익계산서
수익
순이익
| (AUD) | 2024년 6월info | 전년대비 변동 |
|---|---|---|
수익 | 86.56만 | -4.89% |
운영비 | 202.52만 | -10.92% |
순이익 | -1074.42만 | -11.49% |
순이익률 | -1.24천 | -17.23% |
주당 수익 | — | — |
EBITDA | -1121.15만 | -17.52% |
유효 세율 | — | — |
대차대조표
총자산
총부채
| (AUD) | 2024년 6월info | 전년대비 변동 |
|---|---|---|
현금 및 단기 투자 | 1.82억 | 47.37% |
총자산 | 2.02억 | 36.71% |
총부채 | 1205.75만 | 9.82% |
총자기자본 | 1.90억 | — |
발행 주식 | 14.53억 | — |
주가순자산비율 | 14.15 | — |
총자산이익률 | -14.53% | — |
자본이익률 | -15.32% | — |
현금 흐름
순현금흐름
| (AUD) | 2024년 6월info | 전년대비 변동 |
|---|---|---|
순이익 | -1074.42만 | -11.49% |
영업 현금 흐름 | -818.54만 | 30.16% |
투자 현금 흐름 | -1029.98만 | -87,445.92% |
자금 조달 현금 흐름 | 4780.60만 | 25.58% |
순현금흐름 | 2902.76만 | 5.47% |
잉여 현금 흐름 | -609.97만 | -44.31% |
정보
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
설립
2001
웹사이트
직원 수
19
